These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35092183)

  • 21. Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD.
    Nogami A; Yoneda M; Iwaki M; Kobayashi T; Kessoku T; Honda Y; Ogawa Y; Imajo K; Higurashi T; Hosono K; Kirikoshi H; Saito S; Nakajima A
    Sci Rep; 2022 Dec; 12(1):21925. PubMed ID: 36535977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis.
    Chen J; Allen AM; Therneau TM; Chen J; Li J; Hoodeshenas S; Chen J; Lu X; Zhu Z; Venkatesh SK; Song B; Ehman RL; Yin M
    Eur Radiol; 2022 Feb; 32(2):950-958. PubMed ID: 34432123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease.
    Lee HA; Kim SS; Choi JY; Seo YS; Park BJ; Sim KC; Kim SU
    Abdom Radiol (NY); 2022 Nov; 47(11):3733-3745. PubMed ID: 35962809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases.
    Ni XX; Lian M; Wu HM; Li XY; Sheng L; Bao H; Miao Q; Xiao X; Guo CJ; Li H; Ma X; Hua J
    World J Gastroenterol; 2021 Jan; 27(1):80-91. PubMed ID: 33505152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver Fat Quantification by Ultrasound in Children: A Prospective Study.
    D'Hondt A; Rubesova E; Xie H; Shamdasani V; Barth RA
    AJR Am J Roentgenol; 2021 Oct; 217(4):996-1006. PubMed ID: 33438457
    [No Abstract]   [Full Text] [Related]  

  • 27. Diagnostic performance of ultrasound hepatorenal index for the diagnosis of hepatic steatosis in children.
    Frankland MP; Dillman JR; Anton CG; Coley BD; Nasser MP; O'Hara SM; Li Y; Trout AT
    Pediatr Radiol; 2022 Jun; 52(7):1306-1313. PubMed ID: 35229183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients.
    Wang M; Tang S; Li G; Huang Z; Mo S; Yang K; Chen J; Du B; Xu J; Ding Z; Dong F
    BMC Gastroenterol; 2024 Feb; 24(1):81. PubMed ID: 38395765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
    de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
    J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter.
    Elkabany ZA; Hamza RT; Ismail EAR; Elsharkawy A; Yosry A; Musa S; Khalaf MA; Elgawesh RM; Esmat G
    Eur J Gastroenterol Hepatol; 2020 Aug; 32(8):1008-1016. PubMed ID: 31834057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
    Petroff D; Blank V; Newsome PN; Shalimar ; Voican CS; Thiele M; de Lédinghen V; Baumeler S; Chan WK; Perlemuter G; Cardoso AC; Aggarwal S; Sasso M; Eddowes PJ; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Cobbold JF; Naveau S; Lupsor-Platon M; Mueller S; Krag A; Irles-Depe M; Semela D; Wong GL; Wong VW; Villela-Nogueira CA; Garg H; Chazouillères O; Wiegand J; Karlas T
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):185-198. PubMed ID: 33460567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard.
    Ajmera VH; Cachay ER; Ramers CB; Bassirian S; Singh S; Bettencourt R; Richards L; Hamilton G; Middleton M; Fowler K; Sirlin C; Loomba R
    Clin Infect Dis; 2021 Jun; 72(12):2124-2131. PubMed ID: 32975278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic value of FibroTouch in identifying hepatic steatosis in NAFLD with MRI-PDFF as the reference standard.
    Mu R; Xia YC; Zhu KY; Lu JY; Luo Q; Zhang L; Lin RK; Cai XB; Qu Y; Lu LG
    J Dig Dis; 2023 Dec; 24(12):691-701. PubMed ID: 37994615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease.
    Shao CX; Ye J; Dong Z; Li F; Lin Y; Liao B; Feng S; Zhong B
    Ther Adv Chronic Dis; 2021; 12():20406223211033119. PubMed ID: 34408822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal cutoff value for assessing changes in intrahepatic fat amount by using the controlled attenuation parameter in a longitudinal setting.
    Ahn SB; Jun DW; Kang BK; Kim M; Chang M; Nam E
    Medicine (Baltimore); 2018 Dec; 97(50):e13636. PubMed ID: 30558054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
    Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
    Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative evaluation of hepatic steatosis using attenuation imaging in a pediatric population: a prospective study.
    Bulakci M; Ercan CC; Karapinar E; Aksakal MZT; Aliyev S; Bicen F; Sahin AY; Salmaslioglu A
    Pediatr Radiol; 2023 Jul; 53(8):1629-1639. PubMed ID: 36881143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
    Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
    Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of correlation between liver fat fraction and AST and ALT levels in overweight and obese children by using new magnetic resonance imaging technique.
    Pirimoğlu B; Sade R; Polat G; İşlek A; Kantarcı M
    Turk J Gastroenterol; 2020 Feb; 31(2):156-162. PubMed ID: 32141825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.